Jain Keerti, Jain Narendra K
Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Central University, Sagar, MP 470003, India.
Drug Discov Today. 2013 Dec;18(23-24):1272-81. doi: 10.1016/j.drudis.2013.08.005. Epub 2013 Aug 20.
Leishmaniasis reveals itself in two forms, cutaneous and visceral, but the later exerts serious complications and may lead to death, if untreated. The availability of limited number of antileishmanial chemotherapeutic agents, the high cost of treatment, growing incidences of resistance to first line drugs as well as severe toxicities associated with the drugs complicate the treatment of visceral leishmaniasis. To overcome these problems, critical investigation of new therapeutic strategies with potential antileishmanial activity and good tolerability are essential. In this review we explore the different facets of novel therapeutic strategies for treatment of visceral leishmaniasis with a purpose to summarize all the possible treatment tactics, which will help scientists working in this arena to implement their research in a systematic manner.
利什曼病有两种表现形式,即皮肤型和内脏型,但后者会引发严重并发症,若不治疗可能导致死亡。抗利什曼病化疗药物数量有限、治疗费用高昂、对一线药物的耐药性发生率不断上升以及药物相关的严重毒性,都使内脏利什曼病的治疗变得复杂。为克服这些问题,对具有潜在抗利什曼病活性和良好耐受性的新治疗策略进行关键研究至关重要。在本综述中,我们探讨了治疗内脏利什曼病新治疗策略的不同方面,目的是总结所有可能的治疗策略,这将有助于该领域的科学家系统地开展他们的研究。